Development and Demonstration of a Co-feed Process to Address Form and Physical Attribute Control of the Gefapixant (MK-7264) Citrate Active Pharmaceutical Ingredient-Reference-Cited by-同舟云学术

Development and Demonstration of a Co-feed Process to Address Form and Physical Attribute Control of the Gefapixant (MK-7264) Citrate Active Pharmaceutical Ingredient

Published:2021-02-09 Issue:3 Volume:25 Page:541-551
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Mohan Anne E.¹^ORCID,DiBenedetto Michael²,Alwedi Embarek²^ORCID,Ang Yee Swan³,Asi Sihombing Muhammad Sofian Bin³,Chang Hsieh Yao D.²,Cote Aaron¹,Desmond Richard²,Diaz-Santana Anthony⁴,Khong Eric³,Lee Ivan H.²,Liu Wenjun⁵,Maloney Kevin M.²^ORCID,Mattern Keith²,Pridgen Christopher⁶,Ren Hong²^ORCID,Sirk Kevin²,Sirota Eric²^ORCID,Spencer Glenn²,Tao Beata³,Whittington Michael²,Yang Cuixian²,Zhang Si-Wei⁵

Affiliation:

1. Process Research and Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States

2. Process Research and Development, Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States

3. Pharmaceutical Tech Ops, MSD, 50 Tuas West Drive, 638408, Singapore

4. Chemical Commercialization Technology, Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States

5. Analytical Research and Development, Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States

6. Pharmaceutical Commercialization and Technology, Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.0c00488

Reference12 articles.

1. Handbook of Industrial Crystallization

2. Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications

3. Development of a Green and Sustainable Manufacturing Process for Gefapixant Citrate (MK-7264). Part 6: Development of an Improved Commercial Salt Formation Process

4. Meeus, L. Direct Compression Versus Granulation. In Pharmaceutical Technology Europe 2011, 23, (3); https://www.pharmtech.com/view/direct-compression-versus-granulation.

5. Quantification of segregation potential for polydisperse, cohesive, multi-component powders and prediction of tablet die-filling performance – A methodology for practical testing, re-formulation and process design